Figure 4From: Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren's syndrome CXCL13 protein measured by ELISA in mouse lacrimal glands and in sera from Sjögren's patients. Homogenates made from individual lacrimal glands (n = 8) were analyzed for CXCL13 protein levels by ELISA (a,b). CXCL13 protein increased with age/disease progression in lacrimal glands from untreated male NOD mice (a). LTBR-Ig treatment from 8 to 16 weeks reduced CXCL13 content of mouse lacrimal glands (b). Mean concentration of CXCL13 was significantly elevated in serum samples of Sjögren's syndrome patients (n = 27) versus healthy control sera (n = 30) (c). The mean age of Sjögren's syndrome patients was 57.17 +/- 10.10 years, and for controls was 57.55 +/- 21.17 years. There was one man in each group. ELISA, enzyme linked immunosorbant assay; NOD, non-obese diabetic.Back to article page